Working… Menu

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00469469
Recruitment Status : Withdrawn (unable to enroll subjects into the study)
First Posted : May 4, 2007
Last Update Posted : April 22, 2015
Genentech, Inc.
Information provided by:
Dartmouth-Hitchcock Medical Center

Brief Summary:
This is a Phase II study of intravenous Bevacizumab in patients with pathologically confirmed nonresectable primary adrenocortical cancer (ACC). Patients must have received no prior therapy. They will receive Bevacizumab as a single agent every 2 weeks intravenously until disease progression. This study will be open at multiple sites.

Condition or disease Intervention/treatment Phase
Adrenocortical Carcinoma Drug: Bevacizumab Phase 2

Detailed Description:
Adrenocortical carcinoma(ACC)is a rare malignancy with an incidence of 1.5 to 2 per million per year in the United states. Surgery is the only therapeutic option that can prolong survival. Currently there are no therapies that have been proven to prolong survival for patients with nonsurgically resectable disease. ACC has been shown to be highly resistant to standard chemotherapy, therefore, it is important that we test agents with mechanisms of action. This is a single arm phase II study of Bevacizumab, an angiogenesis inhibitor, given as a single agent at 10 mg/kg IV every 2 weeks in patients with unresectable ACC. Bevicizumab will be used as first line therapy. The study will test if Bevacizumab will be able to prolong the time to progression. If a delay in time to progression of 4 months or greater is seen, this will be considered clinically meaningful and further studies will be considered. This study will be conducted at multiple institutions (see below).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex.
Study Start Date : May 2007
Estimated Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Primary Outcome Measures :
  1. To measure time to progression [ Time Frame: From date of first dose of Bevacizumab until progression. ]

Secondary Outcome Measures :
  1. To Measure objective response rate by RECIST [ Time Frame: At the end of treatment, RECIST criteria will be used to determine the patient's best overall response. ]
  2. To determine an adverse event profile [ Time Frame: Measured from date of first treatment until 30 days post treatment. ]
  3. To measure survival in all treated patients. [ Time Frame: Survival is measured from the date of first treatment to date of death form any cause. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must provide written informed consent
  • Subjects must be 18 years of age or older
  • Subjects must have histologically confirmed ACC by the Department of Pathology at Dartmouth-Hitchcock Medical Center
  • Subjects must have inoperable disease
  • This is a first and/or second line study. Patients must have completed only one or fewer regimes of systemic therapy. They may have received one prior systemic therapy either: a) mitotane, or b)chemotherapy, or c) experimental therapy, or d) concurrent chemotherapy and mitotane, or e) no prior systemic therapy
  • Subjects must have a life expectancy of three or more months
  • If subjects have received some form of systemic therapy (e.g. chemotherapy or mitotane), they should have completed that systemic therapy at least 28 days before beginning Bevacizumab
  • All subjects of child-bearing potential(men and women) must agree to the use of effective means of contraception

Exclusion Criteria:

  • Other co-existing malignancies or malignancies diagnosed within the last 5 years wtih the exception of basal cell carcinoma or cervical cancer in situ
  • Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy (except alopecia)
  • absolute neutrophil counts less than 1.5 x l,000,000,000/liter, or platelets less than 20.0 x 1,000,000,000/liter
  • As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory,cardiac, hepatic, or renal disease)
  • Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial
  • Prior therapy with two or more systemic therapy regimes. In other words if a patient is seeking third line therapy or later than third line therapy he is ineligible for this study
  • Current, recent(within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech- sponsored Bevacizumab cancer study
  • Prior use of Bevacizumab or any other anti-VEGF therapies
  • Known hypersensitivity to Bevacizumab
  • Inadequately controlled hypertension (defined as systolic blood pressure of >150 mm Hg and/or diastolic blood pressure >100 mm Hg on anti- hypertensive medications
  • Any prior history of hypertensive crisis or hypertensive encephalopathy
  • Unstable angina
  • New York Heart Association (NYHA)Grade II or greater congestive heart failure
  • History of myocardial infarction within 6 months
  • History of stroke or transient ischemic attack at any time prior to study enrollment
  • Clinically significant peripheral vascular disease
  • Evidence of bleeding diathesis or coagulopathy
  • Presence of central nervous system or brain metastases
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
  • Core biopsies or other minor surgical procedures, excluding placement of a vascular access device, within 7 days prior to Day 0
  • Pregnant (positive pregnancy test) or lactating
  • Women who are fertile and not willing to practice abstinence or an adequate form of contraception (i.e. use or oral contraceptives, intrauterine devices or barrier protection)
  • Urine protein: creatinine ratio > 1.0 at screening -History of abdominal fistula, gastrointestinal perforation, or intr- abdominal abcess within 6 months prior to Day 0
  • Serious, non-healing wound, ulcer, or bone fracture
  • Lung lesions of any etiology(malignant or nonmalignant) in close proximity to a major vessel
  • Cavitary lung lesions (to prevent episodes of potentially life-threatening hemoptysis)
  • History of hemoptysis (defined as bright red blood of 1/2 teaspoon or more)
  • Inability to comply with study and/or follow-up procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00469469

Layout table for location information
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Vivek Samnotra, MD Dartmouth-Hitchcock Medical Center
Layout table for additonal information Identifier: NCT00469469    
Other Study ID Numbers: DMS 0510
First Posted: May 4, 2007    Key Record Dates
Last Update Posted: April 22, 2015
Last Verified: May 2008
Keywords provided by Dartmouth-Hitchcock Medical Center:
Adrenal Cortex
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenocortical Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Adrenal Cortex Neoplasms
Adrenal Gland Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Adrenal Cortex Diseases
Adrenal Gland Diseases
Endocrine System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors